Upcoming Financial Results Announcement by Cellectar Biosciences
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company dedicated to cancer treatment innovations, is preparing to report its first quarter financial results. Scheduled for May 13, the announcement will commence at 8:30 a.m. Eastern Time and will include crucial corporate updates that showcase the company's progress and future plans.
Conference Call Details
The conference call, an important event for investors and stakeholders, will provide insights into financial performance and strategic direction. All interested participants can join the call using the following details:
Conference Call Date & Time
Tuesday, May 13 at 8:30 a.m Eastern Time.
Participation Information
Toll-Free Number: 1-800-717-1738
Conference ID: 53983
Replay Availability
A replay of the conference call will be made accessible shortly after the event. This will allow those unable to attend the live session to catch up on Cellectar’s narratives and corporate strategies. Details regarding how to access the replay will be provided during the call.
About Cellectar Biosciences
Cellectar Biosciences is recognized for its innovative approach to cancer treatment, focusing on the development of proprietary therapeutic agents. The company's principal objective is to utilize its Phospholipid Drug Conjugate™ (PDC) platform, which aims to enhance the effectiveness and safety of therapies by minimizing off-target effects.
Innovative Drug Pipeline
Currently, Cellectar's pipeline features several promising candidates, including:
- iopofosine I 131: This agent is designed for targeted delivery of iodine-131, a radioisotope effective in treating cancer.
- CLR 225: A program utilizing actinium-225, targeting numerous solid tumors where patient needs remain unmet.
- CLR 125: An iodine-125 based program focusing on challenging cancers like triple-negative breast, lung, and colorectal cancers.
Clinical Trials and Recognitions
A notable highlight for the company is the ongoing studies involving iopofosine I 131. It is currently being evaluated in Phase 2b trials aimed at treating relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. Importantly, Cellectar is also engaged in the CLOVER-2 Phase 1b study that focuses on pediatric patients with high-grade gliomas, a move that has opened the possibility for obtaining a Pediatric Review Voucher from the FDA.
The FDA has bestowed multiple designations on iopofosine I 131, acknowledging it as an Orphan Drug, Rare Pediatric Drug, and granting Fast Track status for various cancer treatments. Additionally, European Medicines Agency (EMA) approvals further distinguish the drug, highlighting its Orphan Drug and PRIME designations.
Engaging with Cellectar Biosciences
Cellectar's commitment to cancer treatment extends beyond drug development. The company invites the public and interested stakeholders to explore further information on its efforts and innovations by visiting their official website and engaging through social media platforms, including X, LinkedIn, and Facebook.
Investor Contact Information
Those looking for detailed inquiries can reach out to:
Anne Marie Fields,
Precision AQ,
Phone: 212-362-1200,
Email: annemarie.fields@precisionaq.com
Frequently Asked Questions
What is the main focus of Cellectar Biosciences?
Cellectar Biosciences is dedicated to developing innovative drugs for cancer treatment, utilizing its proprietary PDC platform.
When will the Q1 financial results be reported?
The first quarter financial results will be announced on May 13, starting at 8:30 a.m. Eastern Time.
How can I participate in the conference call?
Interested participants can join by dialing 1-800-717-1738 and using conference ID 53983 on the scheduled date.
What is iopofosine I 131?
It is Cellectar’s lead drug designed for targeted cancer treatment using iodine-131, currently in clinical trials for various indications.
Who can I contact for more information about Cellectar?
For investor inquiries, you can contact Anne Marie Fields at Precision AQ via phone or email, as provided above.
